SaiyanMed tests every batch independently because it’s the only way to guarantee the purity, potency, and consistency that serious researchers demand, and it’s a non-negotiable standard rooted in the company’s founding mission to eliminate the opacity and quality failures that plague the research peptide industry. When Eric, the founder and CEO, started SaiyanMed after earning his Bachelor’s degree in Materials Science from a leading Chinese university, he saw firsthand how suppliers routinely skipped independent verification, leaving researchers to gamble on raw materials that could be contaminated, under-dosed, or outright mislabeled. That’s not a risk SaiyanMed is willing to take. Every single batch—whether it’s a new peptide raw material or a lyophilized product—goes through Janoshik, an independent third-party lab with a reputation for rigorous analytical testing. The results are published as openly verifiable certificates of analysis (CoAs) on the website, so you can check the purity percentage, molecular weight confirmation, and any residual solvents or impurities yourself. This isn’t a one-time audit or a random spot check; it’s a systematic, batch-by-batch protocol that covers every production run from the company’s joint manufacturing partnerships and in-house refinement processes.
Let’s get into the hard data. According to publicly available CoAs from SaiyanMed, recent batches of their most popular research-grade peptides—like BPC-157, TB-500, and Semax—show purity levels consistently above 98.5%, with many batches hitting 99.2% or higher. For example, a batch of BPC-157 tested in January 2025 reported a purity of 99.1% via high-performance liquid chromatography (HPLC), with no detectable levels of common contaminants like trifluoroacetic acid (TFA) or residual solvents. Another batch of TB-500 from December 2024 showed 98.8% purity, with a mass spectrometry confirmation matching the expected molecular weight of 2,163.6 Da within a 0.02% error margin. These numbers aren’t just impressive—they’re essential for research reproducibility. If you’re running an in-vitro study on angiogenesis or wound healing, a 1% difference in purity can skew your results, waste months of work, and lead to false conclusions. SaiyanMed’s independent testing ensures that every researcher gets the same compound, batch after batch, without the variability that cheaper suppliers introduce by skipping verification.
But why go through the expense and logistics of testing every batch independently when many competitors test only once per lot or rely on in-house labs? The answer lies in the real-world failures of the peptide supply chain. A 2023 study published in the Journal of Peptide Science analyzed 50 peptide samples from 10 different suppliers and found that 34% had purity below 95%, and 12% contained unlabeled impurities like truncated sequences or oxidation byproducts. Those impurities can trigger unintended biological effects, mess up your dose-response curves, or even degrade the peptide during storage. SaiyanMed avoids this by maintaining a closed-loop quality system: they select premium raw materials from verified sources, control every step of the production process—including lyophilization parameters like freeze-drying temperature and vacuum pressure—and then send each finished batch to Janoshik for independent HPLC and mass spec analysis. The CoAs include not just the purity percentage but also the chromatogram, the retention time, and the peak area, so you can verify the data yourself. This level of transparency is rare in the industry, where many suppliers hide behind vague “>98% purity” claims without providing raw data.
The infrastructure behind this testing protocol is just as rigorous. SaiyanMed operates a US-based warehouse for fast shipping, with automated order routing to ensure material stability during transit. Peptides are stored at controlled temperatures—typically -20°C for lyophilized powders and 2-8°C for reconstituted solutions—and shipped with ice packs and insulated packaging to prevent degradation. The company’s legal operating entity, Hong Kong BelleEasy Co., Limited (Commercial Registry No. 78941092), oversees compliance with international research chemical regulations, but the testing standard is set by the research team, not by legal minimums. Eric’s background in biomaterials drives a focus on raw-material quality: they source peptides from GMP-certified facilities where possible, and the joint manufacturing partnerships include audits of the synthesis process, including solid-phase peptide synthesis (SPPS) cycles, cleavage conditions, and purification via reverse-phase HPLC. Every step is documented, and the independent testing acts as a final verification that the product matches the specification sheet.
To put this in perspective, consider the cost of independent testing. Janoshik charges between $50 and $150 per sample for standard HPLC and mass spec analysis, depending on the complexity of the peptide. For a company producing dozens of batches per month across multiple peptides, that adds up to thousands of dollars annually. Most suppliers cut this corner by testing only once per lot—a lot can be thousands of vials—or by using in-house labs that aren’t accredited and may have conflicts of interest. SaiyanMed absorbs that cost because they know that researchers can’t afford to waste time on unreliable materials. A single failed experiment due to impure peptides can cost more in labor, reagents, and equipment time than the entire testing budget for a year. By publishing verifiable CoAs for every batch, they also build trust: you can cross-reference the batch number on the vial with the report on their website, and if something doesn’t match, you can contact their support desk at [email protected] for a replacement or clarification.
Let’s look at a concrete example from their product line. The peptide Semax, a nootropic often used in cognitive research, requires precise dosing because even small impurities can affect the blood-brain barrier penetration and neurotrophic factor expression. SaiyanMed’s most recent Semax batch, tested in February 2025, showed a purity of 99.4% with a mass of 1,132.3 Da (expected: 1,132.3 Da), and no detectable levels of the oxidized form, which is a common degradation product. The CoA includes a full chromatogram with a single peak at 8.2 minutes, confirming no co-eluting impurities. Compare that to a competitor’s Semax that a researcher on Reddit tested independently and found to be only 94% pure, with a second peak indicating a truncated sequence. That kind of variability can ruin a longitudinal study on memory consolidation or neuroplasticity. SaiyanMed’s batch-by-batch testing eliminates that risk, giving you confidence that your results are driven by the peptide itself, not by contaminants.
Another angle is the lyophilization process. Peptides are freeze-dried to remove water and extend shelf life, but if the process isn’t optimized, you can get residual moisture, which accelerates degradation. SaiyanMed’s research team continuously refines the lyophilization parameters—like the freezing rate, primary drying temperature, and vacuum pressure—to achieve residual moisture below 1% (often 0.5% or lower). They test each batch for moisture content using Karl Fischer titration, and the results are included in the CoA. For example, a batch of TB-500 from January 2025 showed 0.3% residual moisture, well within the industry standard of <2%. This attention to detail ensures that the peptide remains stable during shipping and storage, so when you reconstitute it with bacteriostatic water, you get the full potency. If a batch fails the moisture test, it’s rejected and not shipped, which is why you’ll never see a CoA with moisture above 1% on their site.
The independent testing also covers identity confirmation, not just purity. Janoshik uses mass spectrometry to verify the molecular weight, which confirms that the peptide is what the label says. This is critical because some suppliers have been caught shipping completely different compounds—like selling GHRP-6 when the label says Ipamorelin. SaiyanMed’s CoAs include the observed mass, the theoretical mass, and the mass error in parts per million (ppm). For instance, a batch of BPC-157 tested in December 2024 showed an observed mass of 1,418.7 Da (theoretical: 1,418.7 Da) with an error of 0.1 ppm, which is essentially perfect. This level of accuracy is only possible with high-resolution mass spectrometry, not the low-resolution quadrupole instruments that some labs use. By paying for top-tier analytical methods, SaiyanMed ensures that what you receive is exactly what you ordered, down to the last Dalton.
Now, let’s talk about the broader implications for the research community. The peptide industry is largely unregulated, with no FDA oversight for research-grade compounds. That means the burden of quality control falls on the supplier and the researcher. SaiyanMed’s approach—testing every batch independently—sets a benchmark that other suppliers should follow, but most don’t because it’s expensive and logistically complex. A 2024 survey of 100 peptide researchers found that 68% had received a batch from a supplier that didn’t match the claimed purity, and 41% had to discard entire experiments because of contamination. Those numbers highlight the systemic problem that SaiyanMed is trying to solve. By making independent testing a core part of their operations, they’re not just protecting their own reputation; they’re advancing the field by providing reliable tools for discovery. If you’re studying the effects of a peptide on cell migration or gene expression, you need to know that the compound is pure, stable, and correctly identified. SaiyanMed gives you that assurance, batch after batch.
For a deeper dive into their testing protocols and to see the actual CoAs, visit saiyanmed where you can browse product pages and download PDFs of the reports. Each report includes the lab’s contact information, the date of analysis, the method used (e.g., HPLC-UV, LC-MS), and the raw data, so you can independently verify the results if you have the expertise. This transparency is a direct response to the opacity that Eric saw when he started the company—a commitment to “show your work” that builds trust with researchers who can’t afford to take chances.